X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (247) 247
maytansine - analogs & derivatives (227) 227
animals (203) 203
index medicus (201) 201
maytansine - pharmacology (191) 191
female (154) 154
trastuzumab (125) 125
mice (109) 109
oncology (108) 108
pharmacology & pharmacy (96) 96
maytansine - therapeutic use (94) 94
antineoplastic agents - pharmacology (84) 84
breast neoplasms - drug therapy (82) 82
cancer (79) 79
cell line, tumor (76) 76
antineoplastic agents - therapeutic use (68) 68
antibodies, monoclonal, humanized - pharmacology (64) 64
maytansine - chemistry (62) 62
antibodies, monoclonal, humanized - therapeutic use (58) 58
maytansine (57) 57
receptor, erbb-2 - metabolism (54) 54
xenograft model antitumor assays (54) 54
maytansine - administration & dosage (52) 52
maytansine - pharmacokinetics (50) 50
breast cancer (47) 47
antibody-drug conjugate (45) 45
immunoconjugates - pharmacology (45) 45
t-dm1 (44) 44
tubulin - metabolism (44) 44
breast neoplasms - pathology (42) 42
trastuzumab emtansine (41) 41
biochemistry & molecular biology (39) 39
breast-cancer (39) 39
therapy (36) 36
analysis (34) 34
chemotherapy (34) 34
phase-ii (34) 34
maytansine - adverse effects (33) 33
middle aged (33) 33
treatment outcome (33) 33
immunoconjugates - therapeutic use (32) 32
mice, nude (32) 32
antibodies, monoclonal, humanized - administration & dosage (31) 31
maytansine - metabolism (31) 31
vinblastine - pharmacology (31) 31
adult (30) 30
antibodies (30) 30
antineoplastic agents - adverse effects (30) 30
cell proliferation - drug effects (30) 30
male (30) 30
aged (29) 29
antibodies, monoclonal, humanized - adverse effects (29) 29
antibodies, monoclonal - therapeutic use (28) 28
antibodies, monoclonal, humanized - pharmacokinetics (28) 28
biopharmaceutics (28) 28
microtubules - drug effects (28) 28
neoplasms - drug therapy (28) 28
antineoplastic agents (27) 27
antineoplastic agents - pharmacokinetics (27) 27
article (27) 27
tumors (27) 27
her2 (26) 26
monoclonal-antibody (26) 26
antibody (25) 25
antineoplastic agents - chemistry (25) 25
medicine, research & experimental (25) 25
pharmacology/toxicology (25) 25
research (25) 25
viral antibodies (25) 25
antibodies, monoclonal - pharmacology (24) 24
breast neoplasms - metabolism (24) 24
dose-response relationship, drug (24) 24
immunoconjugates - chemistry (24) 24
mice, scid (24) 24
receptor, erbb-2 - antagonists & inhibitors (24) 24
antimitotic agents (23) 23
antitumor-activity (23) 23
binding sites (23) 23
care and treatment (22) 22
drug therapy (22) 22
expression (22) 22
kinetics (22) 22
antineoplastic agents - administration & dosage (21) 21
colchicine - pharmacology (21) 21
pertuzumab (21) 21
pharmacokinetics (21) 21
cell survival - drug effects (20) 20
cells (20) 20
clinical trials as topic (20) 20
phase-i (20) 20
rats (20) 20
tubulin (20) 20
chemistry, medicinal (19) 19
immunoconjugate (19) 19
medicine & public health (19) 19
metastasis (19) 19
monoclonal-antibodies (19) 19
antineoplastic agents, phytogenic - pharmacology (18) 18
cattle (18) 18
cytotoxicity (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (358) 358
Chinese (5) 5
Japanese (5) 5
Hungarian (2) 2
French (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2012, Volume 69, Issue 5, pp. 1229 - 1240
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a... 
Trastuzumab emtansine | Medicine & Public Health | Cancer Research | Oncology | Antibody–drug conjugate | T-DM1 | Breast cancer | Pharmacology/Toxicology | HER2 | Antibody-drug conjugate | BREAST-CANCER | ONCOLOGY | PHARMACOLOGY & PHARMACY | MBC | Antibodies, Monoclonal, Humanized - therapeutic use | Enzyme-Linked Immunosorbent Assay | Maytansine - analogs & derivatives | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Tandem Mass Spectrometry | Antibodies, Monoclonal, Humanized - pharmacokinetics | Breast Neoplasms - pathology | Antibodies, Monoclonal, Humanized - pharmacology | Maytansine - pharmacokinetics | Aged, 80 and over | Chromatography, Liquid | Adult | Female | Aged | Trastuzumab | Care and treatment | Oncology, Experimental | Antibodies | Polymerization | Liquid chromatography | Metastasis | Research | Antineoplastic agents | Chromatography | Viral antibodies | Antimitotic agents | Epidermal growth factor | Drug therapy | Mass spectrometry | Cancer | Thrombocytopenia | Epidermal growth factor receptors | Liver | Data processing | Mass spectroscopy | Pharmacology | transaminase | ErbB-2 protein | trastuzumab | Immunogenicity | Microtubules | thioethers | Pharmacokinetics | Platelets | Enzyme-linked immunosorbent assay | Toxicology | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 5097 - 5108
Purpose: An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its... 
ANTIBODY-DRUG CONJUGATE | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | NEU ONCOGENE | METASTATIC BREAST-CANCER | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | PANCREATIC ADENOCARCINOMA | MULTIDRUG-RESISTANCE | TRASTUZUMAB EMTANSINE | AMERICAN SOCIETY | Humans | Immunoconjugates - pharmacokinetics | Macaca fascicularis | Maytansine - pharmacology | Pancreatic Neoplasms - drug therapy | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Trastuzumab - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Maytansine - analogs & derivatives | Rats | Breast Neoplasms - drug therapy | Checkpoint Kinase 1 - metabolism | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Histones - metabolism | Antibody-Dependent Cell Cytotoxicity - drug effects | Camptothecin - pharmacology
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 06/2018, Volume 35, Issue 6, pp. 122 - 14
Purpose An item response theory (IRT) pharmacometric framework is presented to characterize Functional Assessment of Cancer Therapy-Breast (FACT-B) data in... 
ado-trastuzumab emtansine | capecitabine | nonlinear mixed effects | lapatinib | kadcyla | T-DM1 | NONMEM | FACT-B | VALIDATION | TRANSLATION | CHEMISTRY, MULTIDISCIPLINARY | MISSING-DATA | MODELS | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | FUNCTIONAL-ASSESSMENT | TRASTUZUMAB EMTANSINE T-DM1 | ADVERSE EVENTS | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Humans | Capecitabine - pharmacology | Lapatinib - therapeutic use | Treatment Outcome | Capecitabine - therapeutic use | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Lapatinib - pharmacology | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Models, Biological | Adult | Female | Trastuzumab - pharmacology | Longitudinal Studies | Patient Reported Outcome Measures | Antimitotic agents | Care and treatment | Cancer patients | Patient outcomes | Analysis | Breast cancer | Metastasis | Antineoplastic agents | Breast | Mathematical models | Exposure | Pharmacology | Patients | Trastuzumab | Metastases | Cancer | Research Paper | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0131177
Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs, typically exceeding the efficacy of conventional monoclonal... 
RECOMBINANT IMMUNOTOXIN | IMMUNOGENICITY | MULTIDISCIPLINARY SCIENCES | PURIFICATION | SURFACE-PROTEINS | STAPHYLOCOCCUS-AUREUS | ANTITUMOR-ACTIVITY | MONOCLONAL-ANTIBODIES | FRAGMENTATION | CANCER-THERAPY | PROTEIN LIGATION | Cysteine Endopeptidases - chemistry | Staphylococcus aureus - enzymology | Aminoacyltransferases - immunology | Receptor, ErbB-2 - genetics | Humans | Bacterial Proteins - chemistry | Ovarian Neoplasms - pathology | Ki-1 Antigen - immunology | Maytansine - pharmacology | Immunoconjugates - immunology | Immunoconjugates - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Protein Engineering | Maytansine - chemistry | Female | Antineoplastic Agents - pharmacology | Bacterial Proteins - immunology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Oligopeptides - chemistry | Ovarian Neoplasms - drug therapy | Antibodies, Monoclonal - chemistry | Antibodies, Monoclonal - immunology | Aminoacyltransferases - chemistry | Antineoplastic Agents - immunology | Maytansine - analogs & derivatives | Antibodies, Monoclonal - pharmacology | Oligopeptides - immunology | Antineoplastic Agents - chemistry | Immunoconjugates - chemistry | Staphylococcus aureus - chemistry | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Ki-1 Antigen - antagonists & inhibitors | Mice | Antibodies, Monoclonal, Humanized - immunology | Cysteine Endopeptidases - immunology | Maytansine - immunology | Trastuzumab | Antibodies, Monoclonal, Humanized - chemistry | Ki-1 Antigen - genetics | Ovarian Neoplasms - immunology | Monoclonal antibodies | Enzymes | Cysteine | Peptides | Biopharmaceutics | Drugs | Conjugates | Addition polymerization | Ovarian carcinoma | Clinical trials | Pentaglycine | Cancer therapies | Molecular weight | Ovarian cancer | Proteins | Tubulin | CD30 antigen | Xenografts | Medical research | Immunoglobulins | Polypeptides | Cloning | Polymerization | Breast cancer | ErbB-2 protein | Substrates | Chemotherapy | Lysine | Heavy chains | Toxins | Conjugation | Sortase | Tumors | Cancer
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 770 - 780
Abstract Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved for breast, gastric, and gastroesophageal cancers... 
Hematology, Oncology and Palliative Medicine | Human epidermal growth factor 2 | Pertuzumab | Afatinib | Target therapy | Lapatinib | Ado-trastuzumab emtansine | Trastuzumab | Cancer | GYNECOLOGIC-ONCOLOGY-GROUP | IN-SITU HYBRIDIZATION | UROTHELIAL BLADDER-CANCER | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | SALIVARY DUCT CARCINOMA | ONCOLOGY | METASTATIC BREAST-CANCER | AFATINIB BIBW 2992 | GENE AMPLIFICATION | Neoplasms - metabolism | Up-Regulation | Receptor, ErbB-2 - genetics | Humans | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Uterine Cervical Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Maytansine - pharmacology | Breast Neoplasms - metabolism | Peritoneal Neoplasms - drug therapy | Uterine Cervical Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Female | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Peritoneal Neoplasms - secondary | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Uterine Cervical Neoplasms - drug therapy | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Animals | Gene Amplification | Quinazolines - therapeutic use | Peritoneal Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacology | Mutation | Quinazolines - pharmacology | Care and treatment | Biological products | Epidermal growth factor | Lung cancer, Non-small cell | Health aspects
Journal Article
Journal Article
Journal Article